Cognition Therapeutics (CGTX) Gains from Investment Securities (2020 - 2026)
Cognition Therapeutics (CGTX) reported Gains from Investment Securities of $3.6 million for Q1 2026, up 119404.87% on a QoQ basis from $3000.0 in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of Gains from Investment Securities data on file, last reported at $3.6 million in Q1 2026.
- Quarterly Gains from Investment Securities changed N/A year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (changed N/A YoY) and the FY2025 annual result came in at $3.6 million, down 16.43% from the prior year.
- Gains from Investment Securities advanced to $3.6 million in Q1 2026 per CGTX's latest filing, from $3000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $3.6 million in Q1 2026 and bottomed at $3000.0 in Q4 2025.
- The 5-year median for Gains from Investment Securities is $214125.0 (2022), against an average of $582001.9.
- The widest annual swing landed in 2022, when Gains from Investment Securities surged 6038.46%; it then slumped 98.78% in 2023.
- Tracing CGTX's Gains from Investment Securities over 5 years: stood at $21000.0 in 2022, then jumped by 2894.14% to $628769.0 in 2023, then plunged by 89.34% to $67000.0 in 2024, then sank by 95.52% to $3000.0 in 2025, then surged by 119404.87% to $3.6 million in 2026.
- Per Business Quant, the three latest CGTX Gains from Investment Securities figures stand at $3.6 million (Q1 2026), $3000.0 (Q4 2025), and $51000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.59 Mn |
| Mar 31, 2026 | 3.59 Mn |
| Dec 31, 2025 | 3,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | 51,000.00 |
| Sep 30, 2025 | 51,000.00 |
| Dec 31, 2024 | 67,000.00 |
| Dec 31, 2024 | 67,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 247,500.00 |
| Jun 30, 2024 | 247,500.00 |
| Mar 31, 2024 | 195,000.00 |
| Mar 31, 2024 | 195,000.00 |
| Dec 31, 2023 | 628,769.00 |
| Dec 31, 2023 | 628,769.00 |
| Sep 30, 2023 | 19,500.00 |
| Sep 30, 2023 | 19,500.00 |
| Jun 30, 2023 | 576,269.00 |
| Jun 30, 2023 | 576,269.00 |
| Mar 31, 2023 | 412,720.00 |
| Mar 31, 2023 | 412,720.00 |
| Dec 31, 2022 | 21,000.00 |
| Dec 31, 2022 | 21,000.00 |
| Sep 30, 2022 | 1.60 Mn |
| Sep 30, 2022 | 1.60 Mn |
| Jun 30, 2022 | 214,125.00 |
| Jun 30, 2022 | 214,125.00 |
| Mar 31, 2022 | 1.08 Mn |
| Mar 31, 2022 | 1.08 Mn |
| Dec 31, 2021 | 1.47 Mn |
| Dec 31, 2021 | 1.47 Mn |
| Sep 30, 2021 | 26,000.00 |
| Sep 30, 2021 | 26,000.00 |
| Jun 30, 2021 | 11,593.00 |
| Jun 30, 2021 | 11,593.00 |
| Mar 31, 2021 | 22,000.00 |
| Mar 31, 2021 | 22,000.00 |
| Dec 31, 2020 | 1.25 Mn |
| Dec 31, 2020 | 1.25 Mn |